US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Silexion Therapeutics Corp

0.3941

-0.0049-1.23%

Post-market: 0.3752-0.0189-4.80%19:49 EDT

Volume:226.98K

Turnover:88.47K

Market Cap:2.19M

PE:-0.01

High:0.4056

Open:0.3890

Low:0.3770

Close:0.3990

52wk High:80.00

52wk Low:0.3730

Shares:5.56M

Float Shares:5.48M

Volume Ratio:0.47

T/O Rate:4.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-38.7456

EPS(LYR):-89.5962

ROE:-897.46%

ROA:-123.27%

PB:49.80

PE(LYR):0.00

Loading ...

Overview Company News Filings

Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer

Silexion Therapeutics Announces Initiation of Gmp Clinical Supply Manufacturing of Sil204 With Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

THOMSON REUTERS

Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)

Silexion Therapeutics submits SIL204 clinical trial application to Germany

Silexion submits Germany trial application for SIL204 pancreatic cancer study

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s Bfarm for Sil204 in Kras-Driven Locally Advanced Pancreatic Cancer

THOMSON REUTERS

Silexion Therapeutics removes Ilan Levin from board; change effective immediately

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204

Silexion Therapeutics Corp: Expects to Initiate Human Clinical Trials in Q2 of 2026

THOMSON REUTERS

Silexion Therapeutics: to Submit Phase 2/3 Clinical Trial Application in Germany by Qtr-End, Extra Regulatory Filings Across EU in Early 2027

THOMSON REUTERS

Silexion Therapeutics Receives Approval From Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer

THOMSON REUTERS

Israeli Health Ministry clears Silexion Phase 2/3 trial of SIL204 in pancreatic cancer

Silexion Therapeutics reconvened shareholder meeting with 36.6% of shares represented

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)

Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Silexion Therapeutics FY 2025 net loss narrows 27.9% to USD 11.91 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/SLXN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":0.3941,"timestamp":1787342400000,"preClose":0.399,"halted":0,"volume":226975,"hourTrading":{"tag":"盘后","latestPrice":0.3752,"preClose":0.3941,"latestTime":"19:49 EDT","volume":46086,"amount":17405.9704,"timestamp":1787356183525,"change":-0.0189,"changeRate":-0.047957,"amplitude":0.047957},"delay":0,"changeRate":-0.012280701754386003,"floatShares":5482205,"shares":5560300,"eps":-38.74564,"marketStatus":"Market Closed","change":-0.0049,"latestTime":"08-21 16:00:00 EDT","open":0.389,"high":0.4056,"low":0.377,"amount":88465.975738,"amplitude":0.071679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-38.74564,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.399,"preHourTrading":{"tag":"盘前","latestPrice":0.4084,"preClose":0.399,"latestTime":"09:11 EDT","volume":4578,"amount":1821.3487391400001,"timestamp":1787317872853,"change":0.0094,"changeRate":0.023559,"amplitude":0.051128},"postHourTrading":{"tag":"盘后","latestPrice":0.3752,"preClose":0.3941,"latestTime":"19:49 EDT","volume":46086,"amount":17405.9704,"timestamp":1787356183525,"change":-0.0189,"changeRate":-0.047957,"amplitude":0.047957},"volumeRatio":0.4681383366317324},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5482205,"roa":"-123.27%","roe":"-897.46%","lyrEps":-89.596245,"volumeRatio":0.4681383366317324,"shares":5560300,"dividePrice":0,"high":0.4056,"amplitude":0.071679,"preClose":0.399,"low":0.377,"week52Low":0.373,"pbRate":"49.80","week52High":80,"institutionHeld":0,"latestPrice":0.3941,"eps":-38.74564,"divideRate":0,"volume":226975,"delay":0,"ttmEps":-38.74564,"open":0.389,"prevYearClose":19.2,"prevWeekClose":0.4202,"prevMonthClose":1.88,"prevQuarterClose":2.55,"fiveDayClose":0.4202,"twentyDayClose":2.27,"sixtyDayClose":4.163},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-29","symbol":"SLXN","defaultRemindTime":1780061400000,"type":"split","dateTimestamp":1780027200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1785384000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-08-21","current":-0.010171,"percent":0.633333,"low":-1.070842,"twenty":-0.532214,"median":-0.280777,"eighty":-0.100286,"high":-0.012403,"avg":-0.334266,"sd":0.242521,"marketCap":2218542},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094},{"date":"2026-02-20","current":-0.534237,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"marketCap":4940094},{"date":"2026-02-27","current":-0.588338,"twenty":-0.588338,"median":-0.42265,"eighty":-0.127254,"marketCap":5440357},{"date":"2026-03-06","current":-0.557906,"twenty":-0.584956,"median":-0.42723,"eighty":-0.127936,"marketCap":5158959},{"date":"2026-03-13","current":-0.563418,"twenty":-0.591719,"median":-0.432424,"eighty":-0.128618,"marketCap":5209923},{"date":"2026-03-20","current":-0.377654,"twenty":-0.588338,"median":-0.436237,"eighty":-0.128618,"marketCap":4498612},{"date":"2026-03-27","current":-0.366297,"twenty":-0.584956,"median":-0.430786,"eighty":-0.128959,"marketCap":4363328},{"date":"2026-04-02","current":-0.341131,"twenty":-0.584956,"median":-0.423383,"eighty":-0.129233,"marketCap":4063557},{"date":"2026-04-10","current":-0.310374,"twenty":-0.584956,"median":-0.420859,"eighty":-0.131075,"marketCap":3697171},{"date":"2026-04-17","current":-0.279616,"twenty":-0.584956,"median":-0.417583,"eighty":-0.131655,"marketCap":3330785},{"date":"2026-04-24","current":-0.257275,"twenty":-0.583604,"median":-0.415793,"eighty":-0.131962,"marketCap":3064655},{"date":"2026-05-01","current":-0.171153,"twenty":-0.571093,"median":-0.415025,"eighty":-0.132167,"marketCap":2038773},{"date":"2026-05-08","current":-0.145121,"twenty":-0.564344,"median":-0.413413,"eighty":-0.133702,"marketCap":1728677},{"date":"2026-05-15","current":-0.139472,"twenty":-0.562336,"median":-0.409651,"eighty":-0.135442,"marketCap":1661395},{"date":"2026-05-22","current":-0.12255,"twenty":-0.558738,"median":-0.40296,"eighty":-0.131962,"marketCap":1582122},{"date":"2026-05-29","current":-0.138778,"twenty":-0.557906,"median":-0.397852,"eighty":-0.132133,"marketCap":1791622},{"date":"2026-06-05","current":-0.160977,"twenty":-0.557906,"median":-0.386196,"eighty":-0.133327,"marketCap":2078215},{"date":"2026-06-12","current":-0.100286,"twenty":-0.557906,"median":-0.370491,"eighty":-0.132133,"marketCap":1294694},{"date":"2026-06-18","current":-0.09412,"twenty":-0.552496,"median":-0.356785,"eighty":-0.130188,"marketCap":1215085},{"date":"2026-06-26","current":-0.088602,"twenty":-0.543705,"median":-0.341131,"eighty":-0.128209,"marketCap":1143856},{"date":"2026-07-02","current":-0.083896,"twenty":-0.541677,"median":-0.338335,"eighty":-0.124456,"marketCap":1083102},{"date":"2026-07-10","current":-0.084708,"twenty":-0.536943,"median":-0.320891,"eighty":-0.122887,"marketCap":1093576},{"date":"2026-07-17","current":-0.090225,"twenty":-0.534237,"median":-0.31317,"eighty":-0.120908,"marketCap":1164806},{"date":"2026-07-24","current":-0.077243,"twenty":-0.534237,"median":-0.309392,"eighty":-0.118588,"marketCap":997208},{"date":"2026-07-31","current":-0.059717,"twenty":-0.534237,"median":-0.302127,"eighty":-0.117019,"marketCap":770950},{"date":"2026-08-07","current":-0.058095,"twenty":-0.534237,"median":-0.293597,"eighty":-0.113607,"marketCap":750001},{"date":"2026-08-14","current":-0.014929,"twenty":-0.532214,"median":-0.288004,"eighty":-0.102349,"marketCap":192737},{"date":"2026-08-21","current":-0.158944,"twenty":-0.532214,"median":-0.280777,"eighty":-0.100286,"marketCap":2218542}],"updateTime":1787524955877},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635610784","title":"Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635610784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635610784?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:05","pubTimestamp":1778673922,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics began GMP manufacturing of clinical supply for SIL204, positioning next-generation KRAS-targeting siRNA candidate for planned Phase 2/3 trial in locally advanced pancreatic cancer.No trial results have been presented; upcoming study is intended to generate safety and efficacy readouts, starting with safety run-in before moving to randomized stage.Manufactured batches are intended to support first patient dosing, reducing a key execution risk ahead of trial start.Tel Aviv Sourasky Medical Center ethics committee cleared site participation, strengthening near-term clinical start-up prospects alongside ongoing regulatory work in Israel and Germany.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2DjR88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BN0W2W23.USD","SLXN","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635848867","title":"Silexion Therapeutics Announces Initiation of Gmp Clinical Supply Manufacturing of Sil204 With Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2635848867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635848867?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUAP8PPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631546617","title":"Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631546617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631546617?lang=en_us&edition=fundamental","pubTime":"2026-04-29 23:17","pubTimestamp":1777475844,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics, with a price target of $6.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630858305","title":"Silexion Therapeutics submits SIL204 clinical trial application to Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2630858305","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630858305?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:13","pubTimestamp":1777385628,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced the recent successful submission of a clinical trial application, or CTA, to Germany for its planned Phase 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-submits-sil204-clinical-trial-application-to-germany-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-submits-sil204-clinical-trial-application-to-germany-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","SLXN","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630650302","title":"Silexion submits Germany trial application for SIL204 pancreatic cancer study","url":"https://stock-news.laohu8.com/highlight/detail?id=2630650302","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630650302?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:45","pubTimestamp":1777380338,"startTime":"0","endTime":"0","summary":"Silexion submitted Phase 2/3 clinical trial application to Germany BfArM via EU CTIS for SIL204 in KRAS-driven locally advanced pancreatic cancer.Germany will act as reporting member state for EU-wide scientific assessment under EU Clinical Trials Regulation.Company still targets Phase 2/3 trial start in Q2 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL22tCDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4112","NDAQ","SLXN","BK4139","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630130263","title":"Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s Bfarm for Sil204 in Kras-Driven Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630130263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630130263?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:45","pubTimestamp":1777380300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUA8120Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622049150","title":"Silexion Therapeutics removes Ilan Levin from board; change effective immediately","url":"https://stock-news.laohu8.com/highlight/detail?id=2622049150","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622049150?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:07","pubTimestamp":1774469253,"startTime":"0","endTime":"0","summary":"The board approved the removal through a unanimous written determination by the other directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL6XVlWt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621098238","title":"Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2621098238","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621098238?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:50","pubTimestamp":1774360215,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced that it has received formal approval from the Israeli Ministry of Health to initiate its Phase 2/3 clinical ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-approved-to-initiate-phase-2-3-clinical-trial-of-sil204-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-approved-to-initiate-phase-2-3-clinical-trial-of-sil204-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","SLXN","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621106216","title":"Silexion Therapeutics Corp: Expects to Initiate Human Clinical Trials in Q2 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621106216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621106216?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:37","pubTimestamp":1774355843,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0N8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062198","title":"Silexion Therapeutics: to Submit Phase 2/3 Clinical Trial Application in Germany by Qtr-End, Extra Regulatory Filings Across EU in Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062198?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:37","pubTimestamp":1774355843,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0N8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062166","title":"Silexion Therapeutics Receives Approval From Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062166?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:37","pubTimestamp":1774355843,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062113","title":"Israeli Health Ministry clears Silexion Phase 2/3 trial of SIL204 in pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062113?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:37","pubTimestamp":1774355833,"startTime":"0","endTime":"0","summary":"Israel’s Ministry of Health approved Silexion to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.The company said it expects to start human clinical trials in Q2 2026.Silexion plans to submit a Phase 2/3 clinical trial application in Germany by the end of the current quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL4wG8rV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SLXN","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4139","IE00BN0W2V16.EUR","BK4112","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621844540","title":"Silexion Therapeutics reconvened shareholder meeting with 36.6% of shares represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2621844540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621844540?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:32","pubTimestamp":1774297973,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics held a reconvened extraordinary general meeting on March 23, 2026.Shareholders did not approve an increase in authorized share capital by 50,000,000 ordinary shares, from 9,000,000 to 59,000,000.An amendment to the 2024 equity incentive plan’s evergreen provision, effective January 1, 2026, was not approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2JGk1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221708","title":"Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620221708?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:50","pubTimestamp":1773931805,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gossamer-bio-goss-and-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gossamer-bio-goss-and-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4581","BK4585","BK4137","LU0128526141.USD","LU0029874061.USD","SLXN","BK4505","XLV","BK4139","XBI","BK4588","GOSS","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620861405","title":"Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620861405","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620861405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:01","pubTimestamp":1773781260,"startTime":"0","endTime":"0","summary":"Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential. During the fourth quarter, Silexion achieved key clinical readiness milestones including completing two-species toxicology studies, written Scientific Advice from Germany's BfArM, and submission of Phase 2/3 clinical trial application to the Ministry of Health in Israel for SIL204 in locally advanced pancreatic cancer. The Company remains on track to initiate Phase 2/3 clinical trial in the first half of 2026, with Israel regulatory feedback anticipated by the end of Q1 2026. Regulatory Advancement Toward Phase 2/3 Initiation: Silexion received written Scientific Advice from Germany's Federal Institute for Drugs and Medical Devices  regarding the design of its planned Phase 2/3 clinical trial. The Company subsequently submitted its Phase 2/3 clini","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["API","BK4139","BK4007","BK4023","BK4551","SLXN","BK4539","BK4503","BK4535","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620403289","title":"Silexion Therapeutics FY 2025 net loss narrows 27.9% to USD 11.91 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403289?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:49","pubTimestamp":1773780563,"startTime":"0","endTime":"0","summary":"Silexion published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 11.91 million. Research and development expense rose 22.4% to USD 7.14 million, mainly due to higher subcontractor and consultant costs tied to GMP API batches and formulation work ahead of a planned human clinical trial expected in Q2 2026, contingent on regulatory clearance. General and administrative expense fell 33.8% to USD 4.49 million, driven mainly by lower non-cash share-based compensation, partly offset by higher professional services costs related to operating as a public company. Net cash used in operating activities increased 28.6% to USD 10.82 million, while cash and cash equivalents totaled USD 6.0 million as of Dec. 31, 2025. Management said current cash is expected to fund operations for only several months from the filing date and that additional capital will be needed.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4g7dTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":56,"code":"91000000","status":"200"}]}}